AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8724933 — intervention group
Group type: EXPERIMENTAL
Intervention: tutor‐guided instructions
Number of subjects: 90
Study 8724933 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 90
Study 1806627 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 1806627 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 1806627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6313502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg daily)
Number of subjects: 71
Study 6313502 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (1 g daily)
Number of subjects: 71
Study 6313502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine and Cimetidine
Number of subjects: 71
Study 29487077 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional interdisciplinary lifestyle and psychosocial intervention
Number of subjects: 200
Study 29487077 — intervention group
Group type: COMPARATOR
Intervention: Usual care during pregnancy and the first year postpartum
Number of subjects: 200
Study 27385432 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic treatment pre-study followed by prophylaxis on-study
Number of subjects: 118
Study 27385432 — intervention group
Group type: COMPARATOR
Intervention: Hyphenate prophylaxis
Number of subjects: 118
Study 27385432 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized or weekly prophylaxis in B-LONG
Number of subjects: 118
Study 27385432 — intervention group
Group type: COMPARATOR
Intervention: Hyphenate prophylaxis in B-LONG
Number of subjects: 118
Study 24292519 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg ATG
Number of subjects: 224
Study 24292519 — intervention group
Group type: COMPARATOR
Intervention: 10 mg/kg ATG
Number of subjects: 224
Study 21890719 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed antiretroviral therapy
Number of subjects: 76
Study 21890719 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 76
Study 20634743 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (SS)
Number of subjects: 38
Study 20634743 — intervention group
Group type: COMPARATOR
Intervention: Typical warm-up (TWU)
Number of subjects: 38
Study 18377128 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance-based thin-ideal internalization reduction program
Number of subjects: 481
Study 18377128 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy weight control program
Number of subjects: 481
Study 18377128 — intervention group
Group type: COMPARATOR
Intervention: Expressive writing control condition
Number of subjects: 481
Study 18377128 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 481
Study 16036829 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Assist Manikin (VAM) system
Number of subjects: 114
Study 11796426 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal cardioversion (CV)
Number of subjects: 63
Study 11796426 — intervention group
Group type: COMPARATOR
Intervention: External cardioversion (CV)
Number of subjects: 63
Study 10072696 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced talk group (discussed both sets of films with at least three people)
Number of subjects: 0
Study 10072696 — intervention group
Group type: COMPARATOR
Intervention: No talk group (instructed not to discuss the films)
Number of subjects: 0
Study 10072696 — intervention group
Group type: EXPERIMENTAL
Intervention: Talkers group (did not comply with instructions to not discuss the films)
Number of subjects: 0
Study 7745506 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (5 ml/kg dose)
Number of subjects: 215
Study 7745506 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 215
Study 7745506 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant
Number of subjects: 215
Study 7745506 — intervention group
Group type: COMPARATOR
Intervention: Synthetic surfactant and Air placebo
Number of subjects: 215
Study 2183254 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI)
Number of subjects: 0
Study 2183254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7006402 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymacon spin‐cast lenses
Number of subjects: 10
Study 7006402 — intervention group
Group type: COMPARATOR
Intervention: Polymacon lathe‐cut lenses
Number of subjects: 10
Study 31041358 — intervention group
Group type: EXPERIMENTAL
Intervention: Danirixin 15mg IV bid + Oseltamivir 75mg bid
Number of subjects: 10
Study 31041358 — intervention group
Group type: EXPERIMENTAL
Intervention: Danirixin 50mg IV bid + Oseltamivir 75mg bid
Number of subjects: 10
Study 31041358 — intervention group
Group type: COMPARATOR
Intervention: Placebo IV bid + Oseltamivir 75mg bid
Number of subjects: 10
Study 29108794 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized cutting block (CCB)
Number of subjects: 108
Study 29108794 — intervention group
Group type: COMPARATOR
Intervention: Conventional cutting instrument (CCI)
Number of subjects: 108
Study 27353112 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotional memory retrieval
Number of subjects: 91
Study 27353112 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test
Number of subjects: 91
Study 24597931 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue-assisted technique (Group B)
Number of subjects: 60
Study 24597931 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (Group A)
Number of subjects: 60
Study 22342011 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-gloving
Number of subjects: 218
Study 22342011 — intervention group
Group type: COMPARATOR
Intervention: Single-gloving
Number of subjects: 218
Study 22342011 — intervention group
Group type: COMPARATOR
Intervention: Single-gloving (first assistants)
Number of subjects: 218
Study 22342011 — intervention group
Group type: COMPARATOR
Intervention: Single-gloving (scrub nurses)
Number of subjects: 218
Study 22342011 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-gloving (first assistants)
Number of subjects: 218
Study 22342011 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-gloving (scrub nurses)
Number of subjects: 218
Study 22342011 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall perforation occurrence
Number of subjects: 218
Study 22342011 — intervention group
Group type: EXPERIMENTAL
Intervention: Perforation sites
Number of subjects: 218
Study 20853059 — intervention group
Group type: EXPERIMENTAL
Intervention: IORT with EBRT
Number of subjects: 69
Study 20853059 — intervention group
Group type: EXPERIMENTAL
Intervention: IORT alone
Number of subjects: 69
Study 20853059 — intervention group
Group type: EXPERIMENTAL
Intervention: IORT
Number of subjects: 69
Study 20853059 — intervention group
Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 69
Study 18397688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 2 g A 2
Number of subjects: 55
Study 18397688 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 4 g continuously
Number of subjects: 55
Study 18397688 — intervention group
Group type: COMPARATOR
Intervention: Model validation
Number of subjects: 55
Study 15978440 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained group (videotrainer suturing model)
Number of subjects: 17
Study 15978440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 17
Study 14578781 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight dextran 20 cc/hour for 48 hours (n=35)
Number of subjects: 100
Study 14578781 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight dextran 20 cc/hour for 120 hours (n=32)
Number of subjects: 100
Study 14578781 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 325 mg/day for 120 hours (n=27)
Number of subjects: 100
Study 11078287 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 11078287 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 8809502 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine, 40 mg/day
Number of subjects: 32
Study 8809502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1551795 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (75 mg, intramuscular injection)
Number of subjects: 86
Study 1551795 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (intramuscular injection)
Number of subjects: 86
Study 3083922 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 1052
Study 3083922 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy
Number of subjects: 1052
Study 3083922 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave lithotripsy (ESWL)
Number of subjects: 1052
Study 3083922 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy and ESWL
Number of subjects: 1052
Study 31116180 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT
Number of subjects: 0
Study 29239965 — intervention group
Group type: EXPERIMENTAL
Intervention: A.P. Advance
Number of subjects: 168
Study 29239965 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC PM
Number of subjects: 168
Study 29239965 — intervention group
Group type: EXPERIMENTAL
Intervention: KingVision
Number of subjects: 168
Study 26760174 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (12 months)
Number of subjects: 19
Study 26760174 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (0, 5, and 12 months)
Number of subjects: 19
Study 26760174 — intervention group
Group type: COMPARATOR
Intervention: Lean reference subjects (baseline)
Number of subjects: 19
Study 25410432 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending outpatient colorectal clinic
Number of subjects: 36
Study 25410432 — intervention group
Group type: COMPARATOR
Intervention: Non-attending students
Number of subjects: 36
Study 22136516 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA-S (100 mg daily for 3 months)
Number of subjects: 61
Study 22136516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 20701787 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 24
Study 20701787 — intervention group
Group type: COMPARATOR
Intervention: Intensive Insulin Treatment (IIT)
Number of subjects: 24
Study 17062655 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (EE)
Number of subjects: 11
Study 17062655 — intervention group
Group type: COMPARATOR
Intervention: Control interventions (e.g., concentric exercise (CE), stretching, splinting, frictions, ultrasound)
Number of subjects: 11
Study 16003612 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable guided tissue regeneration (GTR) therapy
Number of subjects: 12
Study 16003612 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized bone powder (DBP)
Number of subjects: 12
Study 16003612 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 12
Study 11886971 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 45
Study 11886971 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 45
Study 10440592 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (133 patients, 72 in double-blind period)
Number of subjects: 210
Study 10440592 — intervention group
Group type: COMPARATOR
Intervention: Placebo (77 patients)
Number of subjects: 210
Study 8745803 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization with flexible casting after 3 weeks in plaster casts for 2 weeks
Number of subjects: 90
Study 8745803 — intervention group
Group type: COMPARATOR
Intervention: Conventional short-arm, below the elbow plaster of Paris casts for 5 weeks
Number of subjects: 90
Study 2335101 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/LN (levonorgestrel)
Number of subjects: 0
Study 2335101 — intervention group
Group type: EXPERIMENTAL
Intervention: SHG 415G (gestodene)
Number of subjects: 0
Study 378804 — intervention group
Group type: EXPERIMENTAL
Intervention: 193 mg Fe++ daily for 4 weeks
Number of subjects: 90
Study 378804 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 90
Study 30907187 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 2 or 4 IU daily subcutaneous injection
Number of subjects: 1562
Study 30907187 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 4 IU - 6 weeks pretreatment
Number of subjects: 1562
Study 30907187 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 1562
Study 30907187 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 2PN rate
Number of subjects: 1562
Study 30907187 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) high-quality embryo rate
Number of subjects: 1562
Study 27109856 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual well-being measured by the FACIT-Sp (both M&P and Faith scales)
Number of subjects: 204
Study 27109856 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) assessed by the Neuro-QOL PAWB scale
Number of subjects: 204
Study 27109856 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression assessed by the Patient Health Questionnaire-9 (PHQ-9)
Number of subjects: 204
Study 26119226 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg golimumab
Number of subjects: 220
Study 26119226 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg golimumab
Number of subjects: 220
Study 26119226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 24722160 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib plus gemcitabine (V/G)
Number of subjects: 124
Study 24722160 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus placebo
Number of subjects: 124
Study 22301679 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPSS‐MS intervention (eight‐week program with weekly group sessions and computer‐assisted training)
Number of subjects: 61
Study 22301679 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 61
Study 22301679 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPSS‐MS intervention
Number of subjects: 61
Study 19067772 — intervention group
Group type: EXPERIMENTAL
Intervention: Mock-crime group (participants who damaged and stole CDs)
Number of subjects: 36
Study 19067772 — intervention group
Group type: COMPARATOR
Intervention: No-crime group (participants who did not perform a task)
Number of subjects: 36
Study 17470858 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus best supportive care (BSC)
Number of subjects: 463
Study 17470858 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 463
Study 17470858 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab after crossover from BSC
Number of subjects: 463
Study 15099656 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 95
Study 15099656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 12060017 — intervention group
Group type: EXPERIMENTAL
Intervention: Retraining Method
Number of subjects: 50
Study 12060017 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensation Method
Number of subjects: 50
Study 12060017 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 50
Study 9808597 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ECG ST-T changes and biochemical markers (TnT, TnI, CK-MB mass, myoglobin)
Number of subjects: 516
Study 9808597 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment depression, inverted T waves in >/=5 leads, TnT >/=0.1 microg/L, TnI >/=0.5 microg/L, myoglobin >/=40 microg/L, female sex, age >/=65 years
Number of subjects: 516
Study 7710149 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg sumatriptan SC
Number of subjects: 136
Study 7710149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 2560514 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral THC (10 mg t.i.d. for 3 days and on the morning of the fourth day)
Number of subjects: 17
Study 2560514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2560514 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of THC by inhalation (18 mg/marijuana cigarette)
Number of subjects: 17
Study 2560514 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy THC users
Number of subjects: 17
Study 2560514 — intervention group
Group type: EXPERIMENTAL
Intervention: Light THC users
Number of subjects: 17
Study 6166128 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics combined with pepsin-treated human gamma globulin (Gamma-Venin)
Number of subjects: 146
Study 6166128 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 146
Study 31977883 — intervention group
Group type: EXPERIMENTAL
Intervention: LC09 Granules
Number of subjects: 66
Study 31977883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 31597652 — intervention group
Group type: EXPERIMENTAL
Intervention: whole milk + RE
Number of subjects: 30
Study 31597652 — intervention group
Group type: EXPERIMENTAL
Intervention: skimmed milk + RE
Number of subjects: 30
Study 31597652 — intervention group
Group type: COMPARATOR
Intervention: control drink + RE
Number of subjects: 30
Study 27553588 — intervention group
Group type: EXPERIMENTAL
Intervention: New resuscitation system with face mask
Number of subjects: 36
Study 27553588 — intervention group
Group type: EXPERIMENTAL
Intervention: New resuscitation system with nasal prongs
Number of subjects: 36
Study 27553588 — intervention group
Group type: COMPARATOR
Intervention: T-piece resuscitation system
Number of subjects: 36
Study 25876977 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous catheter (PICC) group
Number of subjects: 104
Study 25876977 — intervention group
Group type: COMPARATOR
Intervention: Conventional puncture group
Number of subjects: 104
Study 24227799 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily real-time teleconsultations for one week between hospital-based nurses and patients with severe COPD (n=132)
Number of subjects: 266
Study 24227799 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=134)
Number of subjects: 266
Study 24227799 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary analysis for both groups
Number of subjects: 266
Study 21332800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk-based human milk fortifier (HMF) added to mother's milk while breastfeeding
Number of subjects: 324
Study 21332800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk-based preterm formula
Number of subjects: 324
Study 21332800 — intervention group
Group type: COMPARATOR
Intervention: Exclusively mother's milk
Number of subjects: 324
Study 21332800 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk-based human milk fortifier (HMF) or preterm formula
Number of subjects: 324
Study 19757993 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to raltegravir
Number of subjects: 170
Study 19757993 — intervention group
Group type: COMPARATOR
Intervention: Maintenance of enfuvirtide
Number of subjects: 170
Study 18534481 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient physiotherapy for 6 weeks (group A)
Number of subjects: 150
Study 18534481 — intervention group
Group type: COMPARATOR
Intervention: No outpatient physiotherapy (group B)
Number of subjects: 150
Study 14998954 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified laser-assisted ICSI
Number of subjects: 1016
Study 14998954 — intervention group
Group type: COMPARATOR
Intervention: Conventional ICSI (control group)
Number of subjects: 1016
Study 11678828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant (80 mg as a single subcutaneous injection)
Number of subjects: 10
Study 11678828 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (3 days)
Number of subjects: 10
Study 11678828 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fasting and pegvisomant
Number of subjects: 10
Study 11678828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9252944 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Enteral Nutrition (TEN)
Number of subjects: 67
Study 9252944 — intervention group
Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 67
Study 8517932 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital 20 mg/kg IV in the first 6 hours of life, then 2.5 mg/kg IV every 12 hours for the next five days
Number of subjects: 60
Study 8517932 — intervention group
Group type: COMPARATOR
Intervention: Not treated with phenobarbital
Number of subjects: 60
Study 8517932 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital treatment
Number of subjects: 60
Study 3646618 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-fed group (up to 30 ml of sterile water at each feeding at 1, 2, and 3 HOL)
Number of subjects: 30
Study 3646618 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed group (fed formula at the same times and in the same amounts as the water-fed group)
Number of subjects: 30
Study 3646618 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine hospital feeding of up to 30 ml of sterile water at 4 HOL and up to 30 ml of formula at 8 HOL)
Number of subjects: 30
Study 3646618 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-fed group
Number of subjects: 30
Study 3646618 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed group
Number of subjects: 30
Study 3646618 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 11302970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 2 kcal/min (high fat)
Number of subjects: 24
Study 11302970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid 0.5 kcal/min (low fat)
Number of subjects: 24
Study 11302970 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 24
Study 31535609 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping interventions
Number of subjects: 240
Study 31535609 — intervention group
Group type: COMPARATOR
Intervention: High-conflict trajectories
Number of subjects: 240